Posted on October 1, 2019 by Sitemaster
From a report presented by Hussain yesterday at the annual meeting of the European Society for Medical Oncology (ESMO) we gained detailed insight into the results of the PROfound trial of olaparib (Lynparza), which had been said to be positive last August. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, gene, Lynparza, mCRPC, metastatic, mutation, olaparib | 3 Comments »
Posted on September 19, 2019 by Sitemaster
A newly published article in Lancet Oncology has suggested that “taxane–platinum combinations have a clinically beneficial role in advanced prostate cancer”. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, carboplatin, castration-resistant, mCRPC, metastatic | 2 Comments »
Posted on August 7, 2019 by Sitemaster
According to a media release issued jointly yesterday by AstraZeneca and Merck, treatment with the PARP inhibitor olaparib (Lynparza) has demonstrated “positive results from the Phase III PROfound trial … in [a subset of] men with metastatic castration-resistant prostate cancer (mCRPC).” … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ATM, BRCA1/2, castration-resistant, mCRPC, metastatic, olaparib, PARP | 2 Comments »
Posted on July 16, 2019 by Sitemaster
A lot of people are hopeful that treatment with a new form of targeted nuclear radiation therapy — lutetium-177 PSMA 617 (177Lu PSMA) — will be able to significantly extend survival of men with metastatic, castration-resistant prostate cancer (mCRPC) … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, lutetium-177, mCRPC, metastatic, NOX66, PSMA | 1 Comment »
Posted on June 9, 2019 by Sitemaster
At the end of May, just prior to the annual meeting of ASCO, the US Food and Drug Administration (FDA) granted fast track designation to an investigational agent called ARV-110 for treatment of metastatic, castration-resistant prostate cancer (mCRPC). … -READ MORE …
Filed under: Drugs in development | Tagged: ARV-110, castration-resistant, fast, FDA, mCRPC, metastatic, track | Leave a comment »
Posted on May 18, 2019 by Sitemaster
We have noted several times in the past that, at least to date, compared to the results shown by the PD-1 and PD-L1 checkpoint inhibitors in the treatment of cancers like lung cancer, kidney cancer, and melanoma, there has been little evidence of the value of these agents in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: atezolizumab. Keytruda, HSPC, mCRPC, nivolumab, Opdivo, PD-1, PD-L1, pembrolizumab, Tecentriq | 7 Comments »
Posted on March 29, 2019 by Sitemaster
Unfortunately we don’t always hear about some interesting clinical trials as early as we would like to. The following is a case in point. … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, castration-resistant, first line, inhibitor, mCRPC, metastatic, olaparib, PARP | 4 Comments »
